{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T18:29:40Z","timestamp":1773512980016,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the EMPOWER\u2010Lung 1 trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, NCT03088540), cemiplimab conferred longer survival than platinum\u2010doublet chemotherapy for advanced non\u2013small cell lung cancer (NSCLC) with programmed cell death\u2010ligand 1 (PD\u2010L1) \u226550%. Patient\u2010reported outcomes were evaluated among trial participants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned cemiplimab 350\u00a0mg every 3\u00a0weeks or platinum\u2010doublet chemotherapy. At baseline and day 1 of each treatment cycle, patients were administered the European Organization for Research and Treatment of Cancer Quality of Life\u2010Core 30 (QLQ\u2010C30) and Lung Cancer Module (QLQ\u2010LC13) questionnaires. Mixed\u2010model repeated measures analysis estimated overall change from baseline for PD\u2010L1 \u226550% and intention\u2010to\u2010treat populations. Kaplan\u2013Meier analysis estimated time to definitive deterioration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In PD\u2010L1 \u226550% patients (cemiplimab, <jats:italic>n<\/jats:italic>\u00a0=\u00a0283; chemotherapy, <jats:italic>n<\/jats:italic>\u00a0=\u00a0280), baseline QLQ\u2010C30 and QLQ\u2010LC13 scores showed moderate\u2010to\u2010high functioning and low symptom burden. Change from baseline favored cemiplimab on global health status\/quality of life (GHS\/QOL), functioning, and most symptom scales. Risk of definitive deterioration across functioning scales was reduced versus chemotherapy; hazard ratios were 0.48 (95% CI, 0.32\u20100.71) to 0.63 (95% CI, 0.41\u20100.96). Cemiplimab showed lower risk of definitive deterioration for disease\u2010related (dyspnea, cough, pain in chest, pain in other body parts, fatigue) and treatment\u2010related symptoms (peripheral neuropathy, alopecia, nausea\/vomiting, appetite loss, constipation, diarrhea) (nominal <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.05). Results were similar in the intention\u2010to\u2010treat population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results support cemiplimab for first\u2010line therapy of advanced NSCLC from the patient's perspective. Improved survival is accompanied by improvements versus platinum\u2010doublet chemotherapy in GHS\/QOL and functioning and reduction in symptom burden.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34477","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T06:09:43Z","timestamp":1667023783000},"page":"118-129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Patient\u2010reported outcomes with cemiplimab monotherapy for first\u2010line treatment of advanced non\u2013small cell lung cancer with PD\u2010L1 of \u226550%: The EMPOWER\u2010Lung 1 study"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-9993","authenticated-orcid":false,"given":"Mahmut","family":"G\u00fcm\u00fc\u015f","sequence":"first","affiliation":[{"name":"Istanbul Medeniyet University, Faculty of Medicine  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh\u2010I","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ivanescu","sequence":"additional","affiliation":[{"name":"IQVIA  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Istinye University Faculty of Medicine Liv Hospital  Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[{"name":"Dnipropetrovsk State Medical Academy City Multifield Clinical Hospital  Dnipropetrovsk Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[{"name":"Cerrahpa\u015fa Medical Faculty Istanbul University\u2010Cerrahpa\u015fa  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Gogishvili","sequence":"additional","affiliation":[{"name":"High Technology Medical Centre  Tbilisi Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haci M.","family":"Turk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Bezmialem Vakif University Medical Faculty  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Trakya University  \u0130skender\/Edirne Merkez\/Edirne Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Harnett","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Mastey","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Naumann","sequence":"additional","affiliation":[{"name":"IQVIA  Reading UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Reaney","sequence":"additional","affiliation":[{"name":"IQVIA  Reading UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Konidaris","sequence":"additional","affiliation":[{"name":"Sanofi  Reading UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medha","family":"Sasane","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri J. S.","family":"Brady","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Li","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Gullo","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Rietschel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Sezer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Ba\u015fkent University  Etimesgut Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_2_8_3_1","unstructured":"American Cancer Society.About lung cancer.https:\/\/www.cancer.org\/cancer\/lung\u2010cancer\/about\/what\u2010is.html. Accessed May 18 2021."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.12.94"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.03.008"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010013\u20101959\u20104"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010015\u20102699\u20104"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/jop.19.00577"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000244"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e318299243b"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2014.06.003"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606774"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32409\u20107"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1917346"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00228\u20102"},{"key":"e_1_2_8_16_1","unstructured":"Regeneron Pharmaceuticals Inc. Sanofi\u2010Aventis US LLC.LIBTAYO\u00ae(cemiplimab\u2010RWLC) injection for intravenous use [prescribing information]. Accessed December 3 2021.https:\/\/www.regeneron.com\/downloads\/libtayo_fpi.pdf"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20102035"},{"key":"e_1_2_8_18_1","unstructured":"European Medicines Agency.Appendix 2 to the guideline on the\u00a0evaluation of anticancer medicinal products in man.The use of patient\u2010reported outcome (PRO) measures in oncology studies. Accessed December 3 2021.https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix\u20102\u2010guideline\u2010evaluation\u2010anticancer\u2010medicinal\u2010products\u2010man_en.pdf"},{"key":"e_1_2_8_19_1","unstructured":"US Food and Drug Administration.Core patient\u2010reported outcomes in cancer clinical trials.Guidance for industry. Draft guidance. Accessed December 3 2021.https:\/\/www.fda.gov\/media\/149994\/download"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959\u20108049(94)90535\u20105"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1998.16.1.139"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010010\u20101016\u20105"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2307\/1164588"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118762516"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010013\u20100583\u20106"},{"key":"e_1_2_8_27_1","volume-title":"EORTC QLQ\u2010C30 reference values","author":"Scott NW","year":"2008"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30690\u20103"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.9594"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102354.2012.01332.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.208"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.694"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3328"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3335"},{"issue":"1","key":"e_1_2_8_35_1","article-title":"Assessing the impact of open\u2010label designs on patient\u2010reported outcomes: a cross\u2010trial investigation in metastatic melanoma [abstract]","volume":"30","author":"Lord\u2010Bessen J","year":"2021","journal-title":"Qual Life Res"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6205"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy181"}],"updated-by":[{"DOI":"10.1002\/cncr.35165","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000}}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.34477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:21:02Z","timestamp":1760268062000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/cncr.34477"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34477","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1002\/cncr.35165","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"2022-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}